Renee Leduc

1.0k total citations
31 papers, 679 citations indexed

About

Renee Leduc is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Renee Leduc has authored 31 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 17 papers in Pathology and Forensic Medicine and 14 papers in Hematology. Recurrent topics in Renee Leduc's work include Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Renee Leduc is often cited by papers focused on Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (15 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Renee Leduc collaborates with scholars based in United States, France and United Kingdom. Renee Leduc's co-authors include Irene M. Ghobrial, Brianna Harris, Edie Weller, Stacey Chuma, Kenneth C. Anderson, Paul G. Richardson, Meghan Rourke, Steven P. Treon, Diane Warren and Xavier Leleu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Renee Leduc

31 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Renee Leduc United States 11 470 402 204 179 173 31 679
David H. Vesole United States 9 144 0.3× 196 0.5× 164 0.8× 178 1.0× 48 0.3× 30 444
Christos Karkantaris Greece 7 194 0.4× 225 0.6× 144 0.7× 59 0.3× 63 0.4× 9 402
Gerasimos Pangalis Greece 9 233 0.5× 184 0.5× 108 0.5× 102 0.6× 75 0.4× 21 376
Dorthe Rønnov‐Jessen Denmark 9 159 0.3× 100 0.2× 293 1.4× 75 0.4× 46 0.3× 14 465
Christine I. Chen Canada 11 290 0.6× 207 0.5× 527 2.6× 425 2.4× 83 0.5× 55 769
Elizabeth Bilotti United States 12 584 1.2× 460 1.1× 385 1.9× 237 1.3× 206 1.2× 29 832
Anna Johnson Sweden 7 605 1.3× 554 1.4× 41 0.2× 88 0.5× 378 2.2× 10 786
Reena Ramsaroop South Africa 12 203 0.4× 56 0.1× 63 0.3× 81 0.5× 64 0.4× 27 509
Uma Borate United States 14 171 0.4× 123 0.3× 482 2.4× 200 1.1× 101 0.6× 90 830
Grigoriy Rekhtman Ukraine 4 165 0.4× 114 0.3× 538 2.6× 445 2.5× 72 0.4× 5 744

Countries citing papers authored by Renee Leduc

Since Specialization
Citations

This map shows the geographic impact of Renee Leduc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renee Leduc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renee Leduc more than expected).

Fields of papers citing papers by Renee Leduc

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renee Leduc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renee Leduc. The network helps show where Renee Leduc may publish in the future.

Co-authorship network of co-authors of Renee Leduc

This figure shows the co-authorship network connecting the top 25 collaborators of Renee Leduc. A scholar is included among the top collaborators of Renee Leduc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renee Leduc. Renee Leduc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mooney, J, Nicola J Spalding, Fiona Poland, et al.. (2014). The informational needs of patients with ANCA-associated vasculitis--development of an informational needs questionnaire. Lara D. Veeken. 53(8). 1414–1421. 15 indexed citations
2.
Grayson, Peter C., Naomi A. Amudala, Carol A. McAlear, et al.. (2014). Causal Attributions about Disease Onset and Relapse in Patients with Systemic Vasculitis. The Journal of Rheumatology. 41(5). 923–930. 12 indexed citations
3.
Grayson, Peter C., Naomi A. Amudala, Carol A. McAlear, et al.. (2013). Illness Perceptions and Fatigue in Systemic Vasculitis. Arthritis Care & Research. 65(11). 1835–1843. 48 indexed citations
4.
Leleu, Xavier, Wanling Xie, Ranjit Banwait, et al.. (2011). The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia. Clinical Cancer Research. 17(9). 3013–3018. 36 indexed citations
5.
Banwait, Ranjit, Kevin O′Regan, Federico Campigotto, et al.. (2011). The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia. American Journal of Hematology. 86(7). 567–572. 36 indexed citations
6.
Ghobrial, Irene M., Morie A. Gertz, Betsy LaPlant, et al.. (2010). Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1408–1414. 102 indexed citations
7.
Ghobrial, Irene M., Wanling Xie, Swaminathan P. Iyer, et al.. (2010). Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. American Journal of Hematology. 85(9). 670–674. 101 indexed citations
8.
9.
Ghobrial, Irene M., Fangxin Hong, Swaminathan P. Iyer, et al.. (2010). Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1422–1428. 116 indexed citations
10.
Ghobrial, Irene M., Aldo M. Roccaro, Fangxin Hong, et al.. (2010). Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia. Clinical Cancer Research. 16(3). 1033–1041. 96 indexed citations
11.
Leduc, Renee, Marybeth Nelson, Amy Sam, et al.. (2009). A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S86–S86. 1 indexed citations
12.
Ghobrial, Irene M., Swaminathan P. Iyer, Stacey Chuma, et al.. (2009). Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia. Journal of Clinical Oncology. 27(15_suppl). 8535–8535. 2 indexed citations
13.
Ghobrial, Irene M., Fangxin Hong, Swaminathan P. Iyer, et al.. (2009). Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. Blood. 114(22). 2727–2727. 5 indexed citations
14.
Leleu, Xavier, Edie Weller, Aldo M. Roccaro, et al.. (2008). Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leukemia & lymphoma. 49(6). 1104–1107. 37 indexed citations
15.
Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2008). Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).. Blood. 112(11). 1010–1010. 2 indexed citations
16.
Leleu, Xavier, Evdoxia Hatjiharissi, Aldo M. Roccaro, et al.. (2007). Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).. Blood. 110(11). 1486–1486. 1 indexed citations
17.
Soumerai, Jacob D., Kelly O’Connor, Christopher J. Patterson, et al.. (2007). Imatinib Mesylate (Gleevec®) Produces Responses in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia.. Blood. 110(11). 2575–2575. 3 indexed citations
18.
Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2007). Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4493–4493. 1 indexed citations
19.
Ghobrial, Irene M., Renee Leduc, Marybeth Nelson, et al.. (2007). Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4496–4496. 3 indexed citations
20.
Ghobrial, Irene M., Swaminathan P. Iyer, Ashraf Badros, et al.. (2007). Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4494–4494. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David H. Vesole Breakdown of academic impact, for papers by Christos Karkantaris Breakdown of academic impact, for papers by Gerasimos Pangalis Breakdown of academic impact, for papers by Dorthe Rønnov‐Jessen Breakdown of academic impact, for papers by Christine I. Chen Breakdown of academic impact, for papers by Elizabeth Bilotti Breakdown of academic impact, for papers by Anna Johnson Breakdown of academic impact, for papers by Reena Ramsaroop Breakdown of academic impact, for papers by Uma Borate Breakdown of academic impact, for papers by Grigoriy Rekhtman
Rankless by CCL
2026